ArticleEuropean journal of heart failure2019
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.
Article in European journal of heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
157 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effectiveness of various exercise interventions on peak VOBMC cardiovascular disorders · 2026Pooled it
- Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies.Frontiers in endocrinology · 2022Pooled it
- Prednisone and azathioprine in patients with inflammatory cardiomyopathy: systematic review and meta-analysis.ESC heart failure · 2020Pooled it
- Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- Myocardial fibrosis and ventricular ectopy in patients with non-ischemic systolic heart failure: results from the DANISH trial.The international journal of cardiovascular imaging · 2022Trial
- Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Trial
- Cardiac fibrosis: mechanistic insights and translational advances.Molecular biomedicine · 2026Review
- Next-generation molecular imaging of cardiac fibrosis.The international journal of cardiovascular imaging · 2026Review
- Amb a 1-Specific IgE in Heart Failure: A Translational Framework for Seasonal Risk, Endotyping, and Patient-Centered Management.Journal of clinical medicine · 2026Review
- Sildenafil Positivity and Chronic Cardiac Pathology in Men Who Died of Ischemic Heart Disease: An Age- and Sex-Matched Postmortem Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
- Ubiquitin-Related Proteostatic Programs in Cycling Fibroblast-Lineage Remodeling After Myocardial Ischemic Injury: A Hypothesis Informed by Single-Cell and Spatial Transcriptomics.International journal of molecular sciences · 2026Review
- Atrial fibrosis in atrial fibrillation: Mechanisms, mapping techniques and clinical applications.The Journal of physiology · 2026Review
- Expression, Localization and Actions of Galectin-3: Implications in the Pathophysiology and Therapy of Cardiovascular Disease.International journal of molecular sciences · 2026Review
- A cardiac fibrosis specific circRNA_006640 sponges miR-7648-3p and miR-185-3p to synergistically up-regulate CTGF.Molecular and cellular biochemistry · 2026Article
- Molecular imaging of immune and fibrosis targets to guide therapy for repair after myocardial infarction.Nature reviews. Cardiology · 2026Review
- A Coupled Inflammatory-Fibrotic-Nitrosative Axis in Patients with Patent Foramen Ovale and Cryptogenic Stroke.Journal of clinical medicine · 2026Article
- Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy.Journal of clinical medicine · 2026Review
- Repressive chromatin regulates fibrotic potential through Suv39h1 in the heart.Cardiovascular research · 2026Article
- Current trends, applications, and challenges in three-dimensional bioprinting for cardiovascular disease models and therapies.iScience · 2026Review
- Injectable, Conductive, Multifunctional Hydrogels with Sustained Luteolin Release for Promoting Myocardial Infarction Repair.ACS applied materials & interfaces · 2026Article
97 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins - resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.